CORNING INC /NY — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CORNING INC /NY filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.63B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $13.12B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $12.59B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $14.19B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $14.08B | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $11.30B | Feb 13, 2023 |
| FY2021 | Dec 31, 2019 | $11.50B | Feb 14, 2022 |
| FY2018 | Dec 31, 2018 | $3.04B | Feb 12, 2019 |
| FY2018 | Sep 30, 2018 | $3.01B | Feb 12, 2019 |
| FY2018 | Jun 30, 2018 | $2.75B | Feb 12, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.62B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $4.28B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $3.93B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $4.51B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $5.06B | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $3.53B | Feb 13, 2023 |
| FY2021 | Dec 31, 2019 | $4.04B | Feb 14, 2022 |
| FY2018 | Dec 31, 2018 | $1.20B | Feb 12, 2019 |
| FY2018 | Sep 30, 2018 | $1.23B | Feb 12, 2019 |
| FY2018 | Jun 30, 2018 | $1.07B | Feb 12, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.60B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $506.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $581.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.32B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $1.91B | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $512.00M | Feb 13, 2023 |
| FY2021 | Dec 31, 2019 | $960.00M | Feb 14, 2022 |
| FY2018 | Dec 31, 2018 | $292.00M | Feb 12, 2019 |
| FY2018 | Sep 30, 2018 | $625.00M | Feb 12, 2019 |
| FY2018 | Jun 30, 2018 | $738.00M | Feb 12, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.28B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.14B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $890.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.44B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $2.11B | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $509.00M | Feb 13, 2023 |
| FY2021 | Dec 31, 2019 | $1.31B | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | $1.58B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $1.61B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $1.42B | Feb 12, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $800.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $800.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $900.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $900.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $800.00M | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $1.00B | Feb 13, 2023 |
| FY2021 | Dec 31, 2019 | $800.00M | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | $807.00M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $689.00M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $637.00M | Feb 12, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.12B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.93B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.84B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.90B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $1.83B | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $1.75B | Feb 13, 2023 |
| FY2021 | Dec 31, 2019 | $1.59B | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | $1.80B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $1.47B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $1.46B | Feb 12, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.70B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.94B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $2.01B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $2.62B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $3.41B | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $2.18B | Feb 13, 2023 |
| FY2021 | Dec 31, 2019 | $2.03B | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | $2.92B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $2.00B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $2.54B | Feb 12, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.98B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $27.74B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $28.50B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $29.50B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $30.15B | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $30.78B | Feb 13, 2023 |
| FY2021 | Dec 31, 2019 | $28.90B | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | $27.51B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $27.49B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $27.90B | Feb 12, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.67B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $16.67B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $16.63B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $17.22B | Feb 12, 2024 |
| FY2022 | Dec 31, 2021 | $17.61B | Feb 13, 2023 |
| FY2021 | Dec 31, 2020 | $17.33B | Feb 14, 2022 |
| FY2020 | Dec 31, 2019 | $15.90B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $13.62B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $11.72B | Feb 12, 2019 |
| FY2017 | Dec 31, 2016 | $9.94B | Feb 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.81B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $10.69B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $11.55B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $12.01B | Feb 12, 2024 |
| FY2022 | Dec 31, 2021 | $12.33B | Feb 13, 2023 |
| FY2021 | Dec 31, 2020 | $13.26B | Feb 14, 2022 |
| FY2020 | Dec 31, 2019 | $12.91B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $13.79B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $15.70B | Feb 12, 2019 |
| FY2017 | Dec 31, 2016 | $17.89B | Feb 15, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.49B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.36B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $2.38B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $2.39B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $2.42B | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $2.46B | Feb 13, 2023 |
| FY2021 | Dec 31, 2019 | $1.94B | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | $1.94B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $1.69B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $1.58B | Feb 12, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.55B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $15.93B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $16.39B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $16.78B | Feb 12, 2024 |
| FY2022 | Dec 31, 2021 | $16.39B | Feb 13, 2023 |
| FY2021 | Dec 31, 2020 | $16.12B | Feb 14, 2022 |
| FY2020 | Dec 31, 2019 | $16.41B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $16.30B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $15.93B | Feb 12, 2019 |
| FY2017 | Dec 31, 2016 | $16.88B | Feb 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.53B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.77B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.78B | Feb 12, 2026 |
| FY2018 | Dec 31, 2018 | $2.36B | Feb 12, 2019 |
| FY2018 | Dec 31, 2017 | $4.32B | Feb 12, 2019 |
| FY2018 | Dec 31, 2016 | $5.29B | Feb 12, 2019 |
| FY2018 | Dec 31, 2015 | $4.50B | Feb 12, 2019 |
| FY2017 | Dec 31, 2014 | $5.31B | Feb 15, 2018 |
| FY2016 | Dec 31, 2013 | $4.70B | Feb 6, 2017 |
| FY2015 | Dec 31, 2012 | $4.99B | Feb 12, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $3.46B | Feb 13, 2013 |
| FY2011 | Dec 31, 2011 | $2.39B | Feb 13, 2012 |
| FY2010 | Dec 31, 2010 | $2.32B | Feb 10, 2011 |
| FY2010 | Dec 31, 2009 | $2.00B | Feb 10, 2011 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 13, 2023 |
| FY2021 | Dec 31, 2019 | 1 | Feb 14, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Feb 12, 2019 |
| FY2018 | Sep 30, 2018 | 0 | Feb 12, 2019 |
| FY2018 | Jun 30, 2018 | 0 | Feb 12, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 13, 2023 |
| FY2021 | Dec 31, 2019 | 1 | Feb 14, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Feb 12, 2019 |
| FY2018 | Sep 30, 2018 | 0 | Feb 12, 2019 |
| FY2018 | Jun 30, 2018 | 0 | Feb 12, 2019 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $566.00M | Feb 10, 2014 |
| FY2012 | Dec 31, 2012 | $472.00M | Feb 13, 2013 |
| FY2011 | Dec 31, 2011 | $354.00M | Feb 13, 2012 |
| FY2010 | Dec 31, 2010 | $313.00M | Feb 10, 2011 |
| FY2009 | Dec 31, 2009 | $312.00M | Feb 10, 2010 |
| FY2009 | Dec 31, 2008 | $313.00M | Feb 10, 2010 |
| FY2009 | Dec 31, 2007 | $158.00M | Feb 10, 2010 |